Previous Close | 8.65 |
Open | 8.65 |
Bid | 8.65 x 43300 |
Ask | 9.15 x 40900 |
Day's Range | 8.65 - 8.65 |
52 Week Range | 8.40 - 16.70 |
Volume | |
Avg. Volume | 0 |
Market Cap | 374.604M |
Beta (5Y Monthly) | 0.02 |
PE Ratio (TTM) | 11.08 |
EPS (TTM) | 0.79 |
Earnings Date | N/A |
Forward Dividend & Yield | 0.31 (3.51%) |
Ex-Dividend Date | Mar 28, 2024 |
1y Target Est | N/A |
Oral Presentation: Sustained Efficacy of STS101 DHE Nasal Powder for the Acute Treatment of Migraine: Results from the Phase3 Double-Blind, Randomized, Placebo-Controlled SUMMIT StudyDURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acut
January 2024 PDUFA date expectedIf approved, STS101 would become the only DHE product evaluated in a randomized, placebo-controlled trial (the SUMMIT trial) against modern outcome measures recommended by both the U.S. Food and Drug Administration (FDA) and International Headache SocietyUnlike current DHE products, STS101 is designed to be easy-to-carry, quick and easy to self-administer within seconds without need for involved administration procedures and to rapidly achieve high drug plasma lev